Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Hengrui Medicine: SHR-1894 Injection Receives Clinical Trial Approval Notification
Hengrui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration for SHR-1894 Injection, and clinical trials will commence soon. SHR-1894 Injection is a biologic drug developed independently by the company, expected to play a role in protecting the skin barrier and suppressing inflammation during the treatment of atopic dermatitis. According to inquiries, there are currently no similar drugs approved for market domestically or internationally. As of now, the total R&D investment in the SHR-1894 injection project has reached approximately 40.1 million yuan.